ANVS 주가 차트
ANVS 재무
Annovis Bio Inc
$1.85
-2.11%
$-0.03
종가: Apr 28, 16:00:00 GMT-4
$1.85
0%
$0
프리마켓: Apr 29, 07:59:19 GMT-4
뒤로
Annovis Bio Inc (ANVS) 재무
주요 통계
이전 종가
$1.89
시가
$1.89
일일 범위
$1.85 - $2
52주 범위
$1.19 - $5.5
거래량
1.3M
평균 거래량
620.0K
배당수익률
--
EPS(TTM)
-1.39
시가총액
$52.4M
ANVS란 무엇인가요?
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). The company is headquartered in Malvern, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2020-01-29. The firm is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
